Century Therapeutics (IPSC) TD Cowen 46th Annual Health Care Conference summary

Strategic priorities and pipeline focus

• Advancing two priority programs: CNTY-813 for Type 1 Diabetes and CNTY-308 for B-cell-mediated autoimmune diseases, both featuring advanced Allo-Evasion 5.0 technology.

• IND submission for CNTY-813 targeted for late 2024, with initial clinical data expected in the second half of 2027 and potential commercialization in the early 2030s.

• CNTY-308 aims to enter the clinic in 2024, leveraging iPSC-derived T cells with robust immune evasion and persistence.

• Long-term vision includes expanding iPSC-derived therapies to additional cell types and diseases, supported by internal vertical integration in biology, engineering, and manufacturing.

• Cash runway extends to Q1 2029, supporting progress through key clinical milestones.

Technology and differentiation

• iPSC-derived therapies offer unlimited scalability and the ability to generate any adult cell type, enabling broad therapeutic applications.

• Allo-Evasion 5.0 incorporates edits to remove HLA Class I/II, add a universal NK inhibitory ligand (CD300a TASR), and express an IgG-degrading protease, providing comprehensive immune protection.

• Preclinical data show superior protection against NK cell and IgG-mediated rejection compared to other technologies.

• CNTY-308’s iPSC-derived T cells mimic autologous T cells in function and persistence, potentially eliminating the need for lymphodepletion.

Clinical development and market opportunity

• CNTY-813 targets a significant unmet need in Type 1 Diabetes, aiming for functional cure by restoring endogenous insulin production and reducing or eliminating immunosuppression.

• Early clinical focus will be on safety, engraftment, insulin independence, and immunosuppression reduction, with pivotal studies modeled after established precedents.

• Initial commercial opportunity in the U.S. includes 60,000+ severe hypoglycemic unaware patients, potentially expanding to 200,000–250,000 with broader eligibility.

• Manufacturing is bioreactor-based and ready for early clinical scale, with plans for further scale-up for commercialization.